BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15135808)

  • 1. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha.
    Ma T; Miyanishi K; Suen A; Epstein NJ; Tomita T; Smith RL; Goodman SB
    Cytokine; 2004 May; 26(3):138-44. PubMed ID: 15135808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W; Bar-Shavit Z
    J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro.
    Gorny G; Shaw A; Oursler MJ
    Exp Cell Res; 2004 Mar; 294(1):149-58. PubMed ID: 14980510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
    Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
    Yamaguchi M; Uchiyama S
    Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
    Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L
    J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
    Abu-Amer Y; Abbas S; Hirayama T
    J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis.
    Mirosavljevic D; Quinn JM; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
    J Bone Miner Res; 2003 Jun; 18(6):984-93. PubMed ID: 12817750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
    Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
    Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
    Wattel A; Kamel S; Prouillet C; Petit JP; Lorget F; Offord E; Brazier M
    J Cell Biochem; 2004 May; 92(2):285-95. PubMed ID: 15108355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
    Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
    Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.